KR100840525B1 - 말 헤르페스바이러스 백신 - Google Patents

말 헤르페스바이러스 백신 Download PDF

Info

Publication number
KR100840525B1
KR100840525B1 KR1020037012273A KR20037012273A KR100840525B1 KR 100840525 B1 KR100840525 B1 KR 100840525B1 KR 1020037012273 A KR1020037012273 A KR 1020037012273A KR 20037012273 A KR20037012273 A KR 20037012273A KR 100840525 B1 KR100840525 B1 KR 100840525B1
Authority
KR
South Korea
Prior art keywords
ehv
vaccine
virus
inactivated
horses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037012273A
Other languages
English (en)
Korean (ko)
Other versions
KR20030085028A (ko
Inventor
멜렌캄프마크더블유
Original Assignee
베링거잉겔하임베트메디카인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거잉겔하임베트메디카인코퍼레이티드 filed Critical 베링거잉겔하임베트메디카인코퍼레이티드
Publication of KR20030085028A publication Critical patent/KR20030085028A/ko
Application granted granted Critical
Publication of KR100840525B1 publication Critical patent/KR100840525B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020037012273A 2001-03-20 2002-01-23 말 헤르페스바이러스 백신 Expired - Lifetime KR100840525B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/812,720 2001-03-20
US09/812,720 US6803041B2 (en) 2001-03-20 2001-03-20 Equine herpesvirus vaccine
PCT/US2002/001644 WO2002074335A2 (en) 2001-03-20 2002-01-23 Equine herpesvirus vaccine

Publications (2)

Publication Number Publication Date
KR20030085028A KR20030085028A (ko) 2003-11-01
KR100840525B1 true KR100840525B1 (ko) 2008-06-24

Family

ID=25210428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037012273A Expired - Lifetime KR100840525B1 (ko) 2001-03-20 2002-01-23 말 헤르페스바이러스 백신

Country Status (15)

Country Link
US (3) US6803041B2 (cg-RX-API-DMAC7.html)
EP (2) EP1923071B1 (cg-RX-API-DMAC7.html)
JP (2) JP4177112B2 (cg-RX-API-DMAC7.html)
KR (1) KR100840525B1 (cg-RX-API-DMAC7.html)
AR (2) AR032984A1 (cg-RX-API-DMAC7.html)
AT (1) ATE392903T1 (cg-RX-API-DMAC7.html)
CA (1) CA2441292C (cg-RX-API-DMAC7.html)
CY (1) CY1108200T1 (cg-RX-API-DMAC7.html)
DE (1) DE60226218T2 (cg-RX-API-DMAC7.html)
DK (2) DK1923071T3 (cg-RX-API-DMAC7.html)
ES (2) ES2428664T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008287A (cg-RX-API-DMAC7.html)
NZ (1) NZ529012A (cg-RX-API-DMAC7.html)
PT (1) PT1372712E (cg-RX-API-DMAC7.html)
WO (1) WO2002074335A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
CA2626875A1 (en) * 2005-11-01 2007-05-10 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US9642908B2 (en) 2008-07-30 2017-05-09 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
CN102257135B (zh) 2008-12-16 2017-06-09 纳米医疗公司 流感疫苗的生产
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
ES2559445T3 (es) * 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
SI3542819T1 (sl) * 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション H3型ウマa型インフルエンザウイルス
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション H3型ウマa型インフルエンザウイルス
US20250114447A1 (en) * 2021-08-06 2025-04-10 Intervet Inc. Vaccine for equine herpesvirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978286A1 (en) * 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4110433A (en) 1976-04-23 1978-08-29 Philips Roxane, Inc. Equine rhinopneumonitis virus
US4083958A (en) 1976-09-13 1978-04-11 The University Of Kentucky Research Foundation Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en) 1979-03-08 1980-09-30 The University Of Illinois Foundation Vaccine for equine rhinopneumonitis
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US5084271B1 (en) 1984-09-11 1997-08-05 Univ Melbourne Vaccine for equine herpesvirus
US4758641A (en) 1987-02-24 1988-07-19 The B F Goodrich Company Polycarboxylic acids with small amount of residual monomer
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en) 1988-11-28 1993-06-22 The B. F. Goodrich Company Crosslinked polyacrylic acid
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
GB9014950D0 (en) 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US6025181A (en) 1990-07-06 2000-02-15 University Court Of The University Of Glasgow Equine herpesvirus-4TK mutant
WO1992002252A1 (en) * 1990-08-01 1992-02-20 Research Corporation Technologies, Inc. The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
DE69333416D1 (de) 1992-06-01 2004-03-18 Univ Melbourne Parkville Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
DE59811284D1 (de) 1997-03-12 2004-06-03 Merck Patent Gmbh Endstück für eine chromatographische säule
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978286A1 (en) * 1998-08-07 2000-02-09 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same

Also Published As

Publication number Publication date
CA2441292A1 (en) 2002-09-26
US20050084502A1 (en) 2005-04-21
WO2002074335A2 (en) 2002-09-26
US7226604B2 (en) 2007-06-05
JP2007197470A (ja) 2007-08-09
DK1372712T3 (da) 2008-08-04
US20070196390A1 (en) 2007-08-23
DE60226218D1 (de) 2008-06-05
DE60226218T2 (de) 2009-05-28
EP1372712B1 (en) 2008-04-23
CA2441292C (en) 2012-03-20
JP4177112B2 (ja) 2008-11-05
MXPA03008287A (es) 2004-10-28
CY1108200T1 (el) 2014-02-12
EP1923071B1 (en) 2013-06-19
JP4668951B2 (ja) 2011-04-13
AR032984A1 (es) 2003-12-03
KR20030085028A (ko) 2003-11-01
EP1923071A1 (en) 2008-05-21
ES2305220T3 (es) 2008-11-01
ATE392903T1 (de) 2008-05-15
DK1923071T3 (da) 2013-08-26
US20030206924A1 (en) 2003-11-06
NZ529012A (en) 2005-08-26
WO2002074335A3 (en) 2003-07-17
AR091235A2 (es) 2015-01-21
JP2004525923A (ja) 2004-08-26
US6803041B2 (en) 2004-10-12
PT1372712E (pt) 2008-05-29
ES2428664T3 (es) 2013-11-08
EP1372712A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
JP4668951B2 (ja) ウマヘルペスウイルスワクチン
KR101056622B1 (ko) 미코플라스마 하이오뉴모니애 및 돼지 바이러스에 대한개선된 배합 백신
KR100874119B1 (ko) 개선된 마이코플라스마 하이오뉴모니애 박테린 백신
US6974577B2 (en) Inactivated bovine scours vaccines, processes and method of preventing bovine scours
JP2015028058A (ja) ウエストナイルウイルスワクチン
TW201731526A (zh) 混成核心之貓科動物疫苗
NZ199561A (en) Vaccine against enzootic abortion in ewes
AU2002245287B2 (en) Equine herpesvirus vaccine
EP0532833A1 (en) Vaccine for equine rhinopneumonitis
AU2002245287A1 (en) Equine herpesvirus vaccine
RU2395297C1 (ru) Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи и лептоспироза крупного рогатого скота
EP2076280B1 (en) Feline influenza vaccine and method of use
RU2257225C1 (ru) Инактивированная эмульсионная вакцина против инфекционного ларинготрахеита птиц

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030919

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20080401

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080618

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110614

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120713

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130607

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130607

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140610

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140610

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150605

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150605

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160613

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160613

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170609

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170609

Start annual number: 10

End annual number: 10

PC1801 Expiration of term

Termination date: 20220723

Termination category: Expiration of duration